Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
IPO Year: 2019
Exchange: NASDAQ
Website: trevitherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/10/2025 | $9.00 → $29.00 | Outperform → Strong Buy | Raymond James |
| 3/10/2025 | $8.00 → $25.00 | Buy | Needham |
| 12/12/2024 | $6.00 → $7.50 | Buy | H.C. Wainwright |
| 9/9/2024 | $6.00 → $7.00 | Outperform | Leerink Partners |
| 8/30/2024 | $6.00 | Buy | H.C. Wainwright |
| 8/30/2024 | $9.00 | Outperform | Raymond James |
| 6/13/2024 | $7.00 | Buy | Rodman & Renshaw |
| 4/12/2023 | $6.00 | Buy | B. Riley Securities |
| 11/22/2022 | $6.00 | Outperform | SVB Leerink |
| 11/11/2021 | $10.00 → $8.00 | Buy | Needham |
Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., May 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC)
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., May 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, May 8, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2025. www.trevith
NEW HAVEN, Conn., April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be participating in the following investor conferences in April. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)">
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie
Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025 Announced positive outcome from sample size re-estimation in the Phase 2b CORAL trial, resulting in no change to study sample size Ended 2024 with $107.6 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Managemen
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., March 11, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 18, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter and year ended December 31, 2024.
Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy in patients with moderate or severe cough counts (p<0.0001) Haduvio is the first and only therapy to show a statistically-significant reduction in chronic cough across both RCC and IPF patients Patient reported and other secondary outcomes were statistically significant and consistent with the primary endpoint Company to host a conference call and webcast today at 8:30 a.m. ET and will be joined by key opinion leader, Professor Jacky Smith NEW HAVEN, Conn., March 10, 2025 /PRNewswire/ -- Trevi Th
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., March 9, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced a conference call and live webcast taking place tomorrow, Monday, March 10th, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2a RIVER trial of Haduvio in patients with refractory chronic cough. www.trevitherapeutics.com
NEW HAVEN, Conn., Feb. 27, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in March. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)">
Topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn., Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF. Topline results continue to be expected in the first half of 2025. www.trevitherapeutics.com (PRN
Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., May 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC)
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., May 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, May 8, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2025. www.trevith
Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025 Announced positive outcome from sample size re-estimation in the Phase 2b CORAL trial, resulting in no change to study sample size Ended 2024 with $107.6 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Managemen
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., March 11, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 18, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter and year ended December 31, 2024.
Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy in patients with moderate or severe cough counts (p<0.0001) Haduvio is the first and only therapy to show a statistically-significant reduction in chronic cough across both RCC and IPF patients Patient reported and other secondary outcomes were statistically significant and consistent with the primary endpoint Company to host a conference call and webcast today at 8:30 a.m. ET and will be joined by key opinion leader, Professor Jacky Smith NEW HAVEN, Conn., March 10, 2025 /PRNewswire/ -- Trevi Th
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., March 9, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced a conference call and live webcast taking place tomorrow, Monday, March 10th, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2a RIVER trial of Haduvio in patients with refractory chronic cough. www.trevitherapeutics.com
Statistically significant lower "Drug Liking" for the 81mg and 162mg doses of oral nalbuphine vs. butorphanol covering our clinical dose range Company to host a conference call and webcast today at 5:00 p.m. ET NEW HAVEN, Conn., Dec. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced positive results from the human abuse potential (HAP) study of oral nalbuphine. ww
Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome expected in December 2024 Ended the third quarter of 2024 with $65.5 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Oct. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2024. www.trevithe
Topline results expected in the fourth quarter of 2024 in the Phase 2a RIVER trial in refractory chronic cough (RCC) Sample size re-estimation milestone is expected in the fourth quarter of 2024 in the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF) Ended the second quarter of 2024 with $69.5 million in cash, cash equivalents and marketable securities with expected cash runway into 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Aug. 8, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the tr
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
10-Q - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
DEFA14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
DEF 14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
144 - Trevi Therapeutics, Inc. (0001563880) (Subject)
S-8 - Trevi Therapeutics, Inc. (0001563880) (Filer)
10-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
144 - Trevi Therapeutics, Inc. (0001563880) (Subject)
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie
NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO). www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte
Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical d
David Clark, MD, MRCP, will lead the continued development of Haduvio™ NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO). Dr. Clark will join Trevi's executive team and be responsible for the strategy and execution of Haduvio's clinical programs.
NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of Lisa Delfini, CPA, as Chief Financial Officer and Danine Summers, as Vice President, Medical Affairs. Ms. Delfini will lead the accounting and finance operations. Ms. Summers will be responsible for educating the medical community on Haduvio's data and development programs through publications, congresses and relationship building with key opinion leaders.
Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications NEW HAVEN, Conn., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of William Forbes, Pharm.D., as Chief Development Officer. Dr. Forbes will join Trevi’s senior management team and be responsible for leading the clinical development of Haduvio which is in late-stage clinical trials in its two lead indications. “I am happy to welcome Bill to our executive leadership team,” sai
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
Raymond James upgraded Trevi Therapeutics from Outperform to Strong Buy and set a new price target of $29.00 from $9.00 previously
Needham reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $25.00 from $8.00 previously
H.C. Wainwright reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $7.50 from $6.00 previously
Leerink Partners resumed coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $7.00 from $6.00 previously
H.C. Wainwright initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $6.00
Raymond James initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $9.00
Rodman & Renshaw initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $7.00
B. Riley Securities initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $6.00
SVB Leerink initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $6.00
Needham reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $8.00 from $10.00 previously